Corrigendum: Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: Final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study (Annals of Oncology (2017) 28:7 (1569-1575) DOI: 10.1093/annonc/mdx193)

M. E. Pavel; E. Baudin; K. E. Öberg; J. D. Hainsworth; M. Voi; N. Rouyrre; M. Peeters; D. J. Gross; J. C. Yao

doi:10.1093/annonc/mdz222

Corrigendum: Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: Final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study (Annals of Oncology (2017) 28:7 (1569-1575) DOI: 10.1093/annonc/mdx193)

M. E. Pavel
, E. Baudin
, K. E. Öberg
, J. D. Hainsworth
, M. Voi
, N. Rouyrre
, M. Peeters
, D. J. Gross
, J. C. Yao

GI Medical Oncology

Research output: Contribution to journal › Comment/debate › peer-review

8 Scopus citations

Abstract

The following funding information has been added: "This work was supported in part by The University of Texas MD Anderson Cancer Center Support Grant P30 CA016672. ".

Original language	English (US)
Pages (from-to)	2010
Number of pages	1
Journal	Annals of Oncology
Volume	30
Issue number	12
DOIs	https://doi.org/10.1093/annonc/mdz222
State	Published - Dec 1 2019

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdz222

Fingerprint

Dive into the research topics of 'Corrigendum: Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: Final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study (Annals of Oncology (2017) 28:7 (1569-1575) DOI: 10.1093/annonc/mdx193)'. Together they form a unique fingerprint.

Cite this

Pavel, M. E., Baudin, E., Öberg, K. E., Hainsworth, J. D., Voi, M., Rouyrre, N., Peeters, M., Gross, D. J., & Yao, J. C. (2019). Corrigendum: Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: Final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study (Annals of Oncology (2017) 28:7 (1569-1575) DOI: 10.1093/annonc/mdx193). Annals of Oncology, 30(12), 2010. https://doi.org/10.1093/annonc/mdz222

Corrigendum: Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: Final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study (Annals of Oncology (2017) 28:7 (1569-1575) DOI: 10.1093/annonc/mdx193). / Pavel, M. E.; Baudin, E.; Öberg, K. E. et al.
In: Annals of Oncology, Vol. 30, No. 12, 01.12.2019, p. 2010.

Research output: Contribution to journal › Comment/debate › peer-review

Pavel, ME, Baudin, E, Öberg, KE, Hainsworth, JD, Voi, M, Rouyrre, N, Peeters, M, Gross, DJ & Yao, JC 2019, 'Corrigendum: Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: Final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study (Annals of Oncology (2017) 28:7 (1569-1575) DOI: 10.1093/annonc/mdx193)', Annals of Oncology, vol. 30, no. 12, pp. 2010. https://doi.org/10.1093/annonc/mdz222

Pavel ME, Baudin E, Öberg KE, Hainsworth JD, Voi M, Rouyrre N et al. Corrigendum: Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: Final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study (Annals of Oncology (2017) 28:7 (1569-1575) DOI: 10.1093/annonc/mdx193). Annals of Oncology. 2019 Dec 1;30(12):2010. doi: 10.1093/annonc/mdz222

Pavel, M. E. ; Baudin, E. ; Öberg, K. E. et al. / Corrigendum : Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: Final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study (Annals of Oncology (2017) 28:7 (1569-1575) DOI: 10.1093/annonc/mdx193). In: Annals of Oncology. 2019 ; Vol. 30, No. 12. pp. 2010.

@article{ee250304c2644e6685a3cff2f29aa20a,

title = "Corrigendum: Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: Final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study (Annals of Oncology (2017) 28:7 (1569-1575) DOI: 10.1093/annonc/mdx193)",

abstract = "The following funding information has been added: {"}This work was supported in part by The University of Texas MD Anderson Cancer Center Support Grant P30 CA016672. {"}.",

author = "Pavel, \{M. E.\} and E. Baudin and {\"O}berg, \{K. E.\} and Hainsworth, \{J. D.\} and M. Voi and N. Rouyrre and M. Peeters and Gross, \{D. J.\} and Yao, \{J. C.\}",

year = "2019",

month = dec,

day = "1",

doi = "10.1093/annonc/mdz222",

language = "English (US)",

volume = "30",

pages = "2010",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

number = "12",

}

TY - JOUR

T1 - Corrigendum

T2 - Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: Final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study (Annals of Oncology (2017) 28:7 (1569-1575) DOI: 10.1093/annonc/mdx193)

AU - Pavel, M. E.

AU - Baudin, E.

AU - Öberg, K. E.

AU - Hainsworth, J. D.

AU - Voi, M.

AU - Rouyrre, N.

AU - Peeters, M.

AU - Gross, D. J.

AU - Yao, J. C.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - The following funding information has been added: "This work was supported in part by The University of Texas MD Anderson Cancer Center Support Grant P30 CA016672. ".

AB - The following funding information has been added: "This work was supported in part by The University of Texas MD Anderson Cancer Center Support Grant P30 CA016672. ".

UR - https://www.scopus.com/pages/publications/85077402628

UR - https://www.scopus.com/pages/publications/85077402628#tab=citedBy

U2 - 10.1093/annonc/mdz222

DO - 10.1093/annonc/mdz222

M3 - Comment/debate

C2 - 31406974

AN - SCOPUS:85077402628

SN - 0923-7534

VL - 30

SP - 2010

JO - Annals of Oncology

JF - Annals of Oncology

IS - 12

ER -

Corrigendum: Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: Final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study (Annals of Oncology (2017) 28:7 (1569-1575) DOI: 10.1093/annonc/mdx193)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this